SCHEMBL880400

SCHEMBL880400

CC(C)(C)c1csc(NC(=N)N)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.54
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
ALDH1A1 P00352 4/20 0.54
LMNA P02545 4/20 0.54
NPSR1 Q6W5P4 3/20 0.54
KDM4E B2RXH2 2/20 0.54
HTT P42858 2/20 0.54
MAPT P10636 2/20 0.54
CCR4 P51679 3/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPK1 P28482 3/20 0.52
POLB P06746 2/20 0.52
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52
TAS1R2 Q8TE23 1/20 0.52
HSD17B10 Q99714 2/20 0.52
HPGD P15428 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475970 0.79 ATAD2 (0.61) ATAD2NPC1RAB9AALDH1A1LMNA
SCHEMBL20788543 0.79 NPC1 (0.77) ATAD2NPC1RAB9AALDH1A1LMNA
SCHEMBL2608447 0.77 ATAD2 (0.63) ATAD2NPC1RAB9AALDH1A1LMNA
SCHEMBL3790984 0.77 NPC1 (0.66) ATAD2NPC1RAB9AALDH1A1LMNA
SCHEMBL3871228 0.77 MAPT (0.54) NPC1RAB9AALDH1A1KDM4EHTT
SCHEMBL77451 0.76 ATAD2 (0.61) ATAD2NPC1RAB9AALDH1A1LMNA
SCHEMBL2086725 0.76 CCR4 (0.56) ATAD2NPC1RAB9AALDH1A1LMNA
Hydrochloric Acid SCHEMBL6989276 0.75 MAPT (0.53) NPC1RAB9AALDH1A1KDM4EHTT
SCHEMBL11222516 0.75 NPC1 (0.62) ATAD2NPC1RAB9AALDH1A1LMNA
SCHEMBL10856806 0.74 KMT2A (0.38) ATAD2NPC1RAB9AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
US-8440705-B2 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2013-05-14 US disclosed
EP-2433634-A2 Compounds, compositions and methods of inhibiting a-synuclein toxicity The Whitehead Institute for Biomedical Research (US) 2012-03-28 EP disclosed
EP-1802303-B1 COMPOUNDS, COMPOSITIONS AND METHODS OF INHIBITING A-SYNUCLEIN TOXICITY WHITEHEAD BIOMEDICAL INST (US) 2011-11-02 EP disclosed
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261953-A1 Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity SNCA, PARK7, HTT ATAD2 1182/4885NPC1 2064/4885RAB9A 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.